LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000A73

Sodium selenite as prophylaxis against erysipelas in secondary lymphedema

Identifieur interne : 000A73 ( PascalFrancis/Corpus ); précédent : 000A72; suivant : 000A74

Sodium selenite as prophylaxis against erysipelas in secondary lymphedema

Auteurs : R. Kasseroller

Source :

Anticancer research [ 0250-7005 ] ; 1998.

RBID : Pascal:98-0480585

Descripteurs français

Pascal (Inist)
- Lymphoedème, Complication, Chirurgie, Tumeur maligne, Glande mammaire, Homme, Sodium Sélénite, Voie externe, Voie locale, Etude cohorte, Sélénium, Erysipèle, Prévention, Randomisation, Etude double insu, Essai clinique, Antiinflammatoire.

English descriptors

KwdEn :
- Antiinflammatory agent, Clinical trial, Cohort study, Complication, Double blind study, Erysipelas, Human, Local administration, Lymphedema, Malignant tumor, Mammary gland, Prevention, Randomization, Selenium, Sodium Selenites, Surgery, Topical administration.

Abstract

In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0250-7005`
A03		`1`		`@0 Anticancer res.`
A05				`@2 18`
A06				`@2 3C`
A08	`01`	`1`	`ENG`	`@1 Sodium selenite as prophylaxis against erysipelas in secondary lymphedema`
A09	`01`	`1`	`ENG`	`@1 Diagnosis and treatment of breast cancer`
A11	`01`	`1`		`@1 KASSEROLLER (R.)`
A12	`01`	`1`		`@1 SCHAUER (A.) @9 ed.`
A12	`02`	`1`		`@1 MEDEN (H.) @9 ed.`
A14	`01`			`@1 Wittlinger's Therapy Center, Alleestrasse 30 @2 6344 Walchsee @3 AUT @Z 1 aut.`
A15	`01`			`@1 Department of Pathology, University of Göttingen, Robert-Koch-Str. 40 @2 37075 Göttingen @3 DEU @Z 1 aut.`
A15	`02`			`@1 Department of Gynecology and Obstetrics, University of Göttingen, Robert-Koch-Str. 40 @2 37075 Göttingen @3 DEU @Z 2 aut.`
A20				`@1 2227-2230`
A21				`@1 1998`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 19426 @5 354000072626610210`
A44				`@0 0000 @1 © 1998 INIST-CNRS. All rights reserved.`
A45				`@0 12 ref.`
A47	`01`	`1`		`@0 98-0480585`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Anticancer research`
A66	`01`			`@0 GRC`
C01	`01`		`ENG`	@0 In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.
C02	`01`	`X`		`@0 002B02S02`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Complication @5 02`
C03	`02`	`X`	`ENG`	`@0 Complication @5 02`
C03	`02`	`X`	`SPA`	`@0 Complicación @5 02`
C03	`03`	`X`	`FRE`	`@0 Chirurgie @5 03`
C03	`03`	`X`	`ENG`	`@0 Surgery @5 03`
C03	`03`	`X`	`SPA`	`@0 Cirugía @5 03`
C03	`04`	`X`	`FRE`	`@0 Tumeur maligne @5 04`
C03	`04`	`X`	`ENG`	`@0 Malignant tumor @5 04`
C03	`04`	`X`	`SPA`	`@0 Tumor maligno @5 04`
C03	`05`	`X`	`FRE`	`@0 Glande mammaire @5 05`
C03	`05`	`X`	`ENG`	`@0 Mammary gland @5 05`
C03	`05`	`X`	`SPA`	`@0 Glándula mamaria @5 05`
C03	`06`	`X`	`FRE`	`@0 Homme @5 06`
C03	`06`	`X`	`ENG`	`@0 Human @5 06`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 06`
C03	`07`	`X`	`FRE`	`@0 Sodium Sélénite @2 NC @2 NA @5 07`
C03	`07`	`X`	`ENG`	`@0 Sodium Selenites @2 NC @2 NA @5 07`
C03	`07`	`X`	`SPA`	`@0 Sodio Selenito @2 NC @2 NA @5 07`
C03	`08`	`X`	`FRE`	`@0 Voie externe @5 08`
C03	`08`	`X`	`ENG`	`@0 Topical administration @5 08`
C03	`08`	`X`	`SPA`	`@0 Vía externa @5 08`
C03	`09`	`X`	`FRE`	`@0 Voie locale @5 09`
C03	`09`	`X`	`ENG`	`@0 Local administration @5 09`
C03	`09`	`X`	`SPA`	`@0 Vía local @5 09`
C03	`10`	`X`	`FRE`	`@0 Etude cohorte @5 10`
C03	`10`	`X`	`ENG`	`@0 Cohort study @5 10`
C03	`10`	`X`	`SPA`	`@0 Estudio cohorte @5 10`
C03	`11`	`X`	`FRE`	`@0 Sélénium @2 NC @5 11`
C03	`11`	`X`	`ENG`	`@0 Selenium @2 NC @5 11`
C03	`11`	`X`	`GER`	`@0 Selen @2 NC @5 11`
C03	`11`	`X`	`SPA`	`@0 Selenio @2 NC @5 11`
C03	`12`	`X`	`FRE`	`@0 Erysipèle @5 13`
C03	`12`	`X`	`ENG`	`@0 Erysipelas @5 13`
C03	`12`	`X`	`SPA`	`@0 Erisipela @5 13`
C03	`13`	`X`	`FRE`	`@0 Prévention @5 17`
C03	`13`	`X`	`ENG`	`@0 Prevention @5 17`
C03	`13`	`X`	`SPA`	`@0 Prevención @5 17`
C03	`14`	`X`	`FRE`	`@0 Randomisation @5 18`
C03	`14`	`X`	`ENG`	`@0 Randomization @5 18`
C03	`14`	`X`	`SPA`	`@0 Aleatorización @5 18`
C03	`15`	`X`	`FRE`	`@0 Etude double insu @5 19`
C03	`15`	`X`	`ENG`	`@0 Double blind study @5 19`
C03	`15`	`X`	`SPA`	`@0 Estudio doble ciego @5 19`
C03	`16`	`X`	`FRE`	`@0 Essai clinique @5 20`
C03	`16`	`X`	`ENG`	`@0 Clinical trial @5 20`
C03	`16`	`X`	`SPA`	`@0 Ensayo clínico @5 20`
C03	`17`	`X`	`FRE`	`@0 Antiinflammatoire @5 21`
C03	`17`	`X`	`ENG`	`@0 Antiinflammatory agent @5 21`
C03	`17`	`X`	`SPA`	`@0 Antiinflamatorio @5 21`
C07	`01`	`X`	`FRE`	`@0 Streptococcie`
C07	`01`	`X`	`ENG`	`@0 Streptococcal infection`
C07	`01`	`X`	`SPA`	`@0 Estreptococia`
C07	`02`	`X`	`FRE`	`@0 Bactériose`
C07	`02`	`X`	`ENG`	`@0 Bacteriosis`
C07	`02`	`X`	`SPA`	`@0 Bacteriosis`
C07	`03`	`X`	`FRE`	`@0 Infection`
C07	`03`	`X`	`ENG`	`@0 Infection`
C07	`03`	`X`	`SPA`	`@0 Infección`
C07	`04`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`04`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`04`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Lymphatique pathologie @5 38`
C07	`05`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Glande mammaire pathologie @5 45`
C07	`06`	`X`	`ENG`	`@0 Mammary gland diseases @5 45`
C07	`06`	`X`	`SPA`	`@0 Glándula mamaria patología @5 45`
N21				`@1 313`

Format Inist (serveur)

NO :	PASCAL 98-0480585 INIST
ET :	Sodium selenite as prophylaxis against erysipelas in secondary lymphedema
AU :	KASSEROLLER (R.); SCHAUER (A.); MEDEN (H.)
AF :	Wittlinger's Therapy Center, Alleestrasse 30/6344 Walchsee/Autriche (1 aut.); Department of Pathology, University of Göttingen, Robert-Koch-Str. 40/37075 Göttingen/Allemagne (1 aut.); Department of Gynecology and Obstetrics, University of Göttingen, Robert-Koch-Str. 40/37075 Göttingen/Allemagne (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Anticancer research; ISSN 0250-7005; Grèce; Da. 1998; Vol. 18; No. 3C; Pp. 2227-2230; Bibl. 12 ref.
LA :	Anglais
EA :	In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.
CC :	002B02S02
FD :	Lymphoedème; Complication; Chirurgie; Tumeur maligne; Glande mammaire; Homme; Sodium Sélénite; Voie externe; Voie locale; Etude cohorte; Sélénium; Erysipèle; Prévention; Randomisation; Etude double insu; Essai clinique; Antiinflammatoire
FG :	Streptococcie; Bactériose; Infection; Appareil circulatoire pathologie; Lymphatique pathologie; Glande mammaire pathologie
ED :	Lymphedema; Complication; Surgery; Malignant tumor; Mammary gland; Human; Sodium Selenites; Topical administration; Local administration; Cohort study; Selenium; Erysipelas; Prevention; Randomization; Double blind study; Clinical trial; Antiinflammatory agent
EG :	Streptococcal infection; Bacteriosis; Infection; Cardiovascular disease; Lymphatic vessel disease; Mammary gland diseases
GD :	Selen
SD :	Linfedema; Complicación; Cirugía; Tumor maligno; Glándula mamaria; Hombre; Sodio Selenito; Vía externa; Vía local; Estudio cohorte; Selenio; Erisipela; Prevención; Aleatorización; Estudio doble ciego; Ensayo clínico; Antiinflamatorio
LO :	INIST-19426.354000072626610210
ID :	98-0480585

Links to Exploration step

Pascal:98-0480585

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sodium selenite as prophylaxis against erysipelas in secondary lymphedema</title>
<author><name sortKey="Kasseroller, R" sort="Kasseroller, R" uniqKey="Kasseroller R" first="R." last="Kasseroller">R. Kasseroller</name>
<affiliation><inist:fA14 i1="01"><s1>Wittlinger's Therapy Center, Alleestrasse 30</s1>
<s2>6344 Walchsee</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0480585</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0480585 INIST</idno>
<idno type="RBID">Pascal:98-0480585</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A73</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sodium selenite as prophylaxis against erysipelas in secondary lymphedema</title>
<author><name sortKey="Kasseroller, R" sort="Kasseroller, R" uniqKey="Kasseroller R" first="R." last="Kasseroller">R. Kasseroller</name>
<affiliation><inist:fA14 i1="01"><s1>Wittlinger's Therapy Center, Alleestrasse 30</s1>
<s2>6344 Walchsee</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Anticancer research</title>
<title level="j" type="abbreviated">Anticancer res.</title>
<idno type="ISSN">0250-7005</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Anticancer research</title>
<title level="j" type="abbreviated">Anticancer res.</title>
<idno type="ISSN">0250-7005</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiinflammatory agent</term>
<term>Clinical trial</term>
<term>Cohort study</term>
<term>Complication</term>
<term>Double blind study</term>
<term>Erysipelas</term>
<term>Human</term>
<term>Local administration</term>
<term>Lymphedema</term>
<term>Malignant tumor</term>
<term>Mammary gland</term>
<term>Prevention</term>
<term>Randomization</term>
<term>Selenium</term>
<term>Sodium Selenites</term>
<term>Surgery</term>
<term>Topical administration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Complication</term>
<term>Chirurgie</term>
<term>Tumeur maligne</term>
<term>Glande mammaire</term>
<term>Homme</term>
<term>Sodium Sélénite</term>
<term>Voie externe</term>
<term>Voie locale</term>
<term>Etude cohorte</term>
<term>Sélénium</term>
<term>Erysipèle</term>
<term>Prévention</term>
<term>Randomisation</term>
<term>Etude double insu</term>
<term>Essai clinique</term>
<term>Antiinflammatoire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0250-7005</s0>
</fA01>
<fA03 i2="1"><s0>Anticancer res.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>3C</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Sodium selenite as prophylaxis against erysipelas in secondary lymphedema</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Diagnosis and treatment of breast cancer</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>KASSEROLLER (R.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>SCHAUER (A.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>MEDEN (H.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Wittlinger's Therapy Center, Alleestrasse 30</s1>
<s2>6344 Walchsee</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Department of Pathology, University of Göttingen, Robert-Koch-Str. 40</s1>
<s2>37075 Göttingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Department of Gynecology and Obstetrics, University of Göttingen, Robert-Koch-Str. 40</s1>
<s2>37075 Göttingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>2227-2230</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>19426</s2>
<s5>354000072626610210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>12 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0480585</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Anticancer research</s0>
</fA64>
<fA66 i1="01"><s0>GRC</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Complication</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Complication</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Complicación</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Surgery</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Glande mammaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Mammary gland</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Glándula mamaria</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Sodium Sélénite</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Sodium Selenites</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Sodio Selenito</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Voie externe</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Topical administration</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vía externa</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Voie locale</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Local administration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Vía local</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Sélénium</s0>
<s2>NC</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Selenium</s0>
<s2>NC</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="GER"><s0>Selen</s0>
<s2>NC</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Selenio</s0>
<s2>NC</s2>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Erysipèle</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Erysipelas</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Erisipela</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Prévention</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Prevention</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Prevención</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Randomization</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Antiinflammatoire</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Antiinflammatory agent</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Antiinflamatorio</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Streptococcie</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Streptococcal infection</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Estreptococia</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Bactériose</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s5>45</s5>
</fC07>
<fN21><s1>313</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 98-0480585 INIST</NO>
<ET>Sodium selenite as prophylaxis against erysipelas in secondary lymphedema</ET>
<AU>KASSEROLLER (R.); SCHAUER (A.); MEDEN (H.)</AU>
<AF>Wittlinger's Therapy Center, Alleestrasse 30/6344 Walchsee/Autriche (1 aut.); Department of Pathology, University of Göttingen, Robert-Koch-Str. 40/37075 Göttingen/Allemagne (1 aut.); Department of Gynecology and Obstetrics, University of Göttingen, Robert-Koch-Str. 40/37075 Göttingen/Allemagne (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Anticancer research; ISSN 0250-7005; Grèce; Da. 1998; Vol. 18; No. 3C; Pp. 2227-2230; Bibl. 12 ref.</SO>
<LA>Anglais</LA>
<EA>In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.</EA>
<CC>002B02S02</CC>
<FD>Lymphoedème; Complication; Chirurgie; Tumeur maligne; Glande mammaire; Homme; Sodium Sélénite; Voie externe; Voie locale; Etude cohorte; Sélénium; Erysipèle; Prévention; Randomisation; Etude double insu; Essai clinique; Antiinflammatoire</FD>
<FG>Streptococcie; Bactériose; Infection; Appareil circulatoire pathologie; Lymphatique pathologie; Glande mammaire pathologie</FG>
<ED>Lymphedema; Complication; Surgery; Malignant tumor; Mammary gland; Human; Sodium Selenites; Topical administration; Local administration; Cohort study; Selenium; Erysipelas; Prevention; Randomization; Double blind study; Clinical trial; Antiinflammatory agent</ED>
<EG>Streptococcal infection; Bacteriosis; Infection; Cardiovascular disease; Lymphatic vessel disease; Mammary gland diseases</EG>
<GD>Selen</GD>
<SD>Linfedema; Complicación; Cirugía; Tumor maligno; Glándula mamaria; Hombre; Sodio Selenito; Vía externa; Vía local; Estudio cohorte; Selenio; Erisipela; Prevención; Aleatorización; Estudio doble ciego; Ensayo clínico; Antiinflamatorio</SD>
<LO>INIST-19426.354000072626610210</LO>
<ID>98-0480585</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A73 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000A73 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:98-0480585
   |texte=   Sodium selenite as prophylaxis against erysipelas in secondary lymphedema
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Sodium selenite as prophylaxis against erysipelas in secondary lymphedema

Sodium selenite as prophylaxis against erysipelas in secondary lymphedema

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri